In the phase 3 RESONATE trial, ibrutinib significantly improved the progression-free survival (PFS) and overall survival (OS) of patients with R/R CLL/SLL, including those with TP53 aberrations [2]. The gene discussed is TP53; the disease is B-cell chronic lymphocytic leukemia.